• Thursday, 3 September 2015
  • Friday, 4 September 2015
  • Saturday, 5 September 2015
  • Sunday, 6 September 2015
General Session
State-of-the-Art Lecture
Symposium
Industry Symposium
Workshop
TIME
13:00
18:40
Pre-Conference Workshop on Immunopathogenesis and Immunotherapy in HCC
The pre-conference workshop is subject to an additional registration.
To attend this workshop, full conference registration is compulsory.
08:00
09:30

ILCA Symposium 1: Emerging Concepts for Understanding Liver Cancer
Chairs: Tania Roskams, MD (Belgium) and Xin Wei Wang, PhD (USA)

Integrated Molecular-Morphological Classification of HCC
Michiie Sakamoto, MD, PhD (Japan)

Cancer Mutanome Immunotherapy
Ugur Sahin, MD (Germany)

Significance of Mixed Hepatocellular – Cholangiocarcinoma
Gregory J. Gores, MD (USA)

Ectopic Lymphoid Structures as Microniches for Tumour Progenitor Cells
Eli Pikarsky, MD, PhD (Israel)

09:30
10:30
State-of-the-Art Lecture 1: The Gut-Liver Axis: Microbiome and HCC
Chair: Peter R. Galle, MD, PhD (Germany)
Robert Schwabe, MD (USA)
10:30
11:00
Coffee & Networking Break
11:00
11:15
Welcome Address
Peter R. Galle, MD, PhD (Germany)
Riccardo Lencioni, MD, PhD (Italy)
Morris Sherman, MD, PhD (Canada)
11:15
12:45
General Session 1: Molecular Pathogenesis of Liver Cancer I.
Chairs: Snorri Thorgeirsson, MD, PhD (USA) and Jessica Zucman-Rossi, MD, PhD (France)
12:45
13:00
Session Break
13:00
14:30
Bayer Lunch Symposium
14:30
14:45
Session Break
14:45
16:15
General Session 2: Molecular Pathogenesis of Liver Cancer II.
Chairs: Masatoshi Kudo, MD, PhD (Japan) and Ann-Lii Cheng, MD, PhD (Taiwan)
16:15
16:45
Coffee & Networking Break
16:45
18:15
ILCA Symposium 2: Controversies in Liver Cancer (Pros and Cons Session)
Chairs: Josep M. Llovet, MD (Spain/USA) and Kim Olthoff, MD (USA)
Liver Resection: Patients within/beyond the Guidelines
Norihiro Kokudo, MD, PhD (Japan) vs. Pietro E. Majno, MD (Switzerland)
BCLC is the Gold Standard: yes/no
Jordi Bruix, MD (Spain) vs. Ronnie Poon, MD, PhD (P.R. China)
Sorafenib Therapy in Child B
Jorge Marrero, MD (USA) vs. Luigi Bolondi, MD (Italy)
18:15
19:00
Welcome Reception
07:30
08:30
Celsion Symposium
08:30
10:00
General Session 3: Epidemiology, Staging and Prognosis
Chairs: Kwang-Hyub Han, MD (Republic of Korea) and Andrew Zhu, MD, PhD (USA)
10:00
11:00
e-Poster Viewing Tour & Networking Break
11:00
12:30
Plenary Session
Chairs: Peter R. Galle, MD, PhD (Germany), Riccardo Lencioni, MD, PhD (Italy) and Morris Sherman, MD, PhD (Canada)
12:30
12:45
Session Break
12:45
14:00

ILCA Special Interest Groups (SIGs) Luncheon Workshops

SIG 1: Molecular Classification and Signalling Pathways
Animal Models Relevant to Human Liver Cancer

Chairs: Xin Wei Wang, PhD (USA) and Wen Xue, PhD (USA)

SIG 2: Surveillance, Biomarkers and Molecular Pathology
HCC Early Detection

Chairs: Amit Singal, MD (USA) and Massimo G. Colombo, MD (Italy)

SIG 3: Imaging and Loco-Regional Therapies
Standardising TACE – Defining TACE Failure
Chairs: Riad Salem, MD (USA) and Bruno Sangro, MD, PhD (Spain)

SIG 4: Target and Systemic Therapies
Hepatocellular Carcinoma with Stem Cell Features: How Can We Define and Handle Them
Chairs: Joong-Won Park, MD, PhD (Republic of Korea) and Tim Meyer, MD, PhD (United Kingdom)

SIG 5: Liver Surgery and Transplantation
Surgery and Transplantation

Chairs: Thomas Decaens, MD, PhD (France) and Katsuhiko Yanaga, MD, PhD (Japan)

SIG 6: Non-HCC Hepatic Malignancies
Update Systemic Therapy

Chairs: Shahid A. Khan, MD, PhD (United Kingdom) and Gregory J. Gores, MD (USA)

12:45
14:00
Luncheon Workshop: Egypt Meets ILCA
Common Approaches and Regional Disparities
Chairs: Peter R. Galle, MD, PhD (Germany) and Mahmoud El Meteini, MD (Egypt)
14:00
14:15
Session Break
14:15
15:45
General Session 4: Diagnosis and Curative Treatment
Chairs: Sandrine Faivre, MD, PhD (France) and Myron Schwartz, MD (USA)
15:45
16:45
e-Poster Viewing Tour & Networking Break
16:45
18:30
ILCA Symposium 3: Advances in Transarterial Treatment of HCC
Chairs: Peter R. Galle, MD, PhD (Germany) and Richard Finn, MD (USA)
TACE for HCC: What We Know, and What We Need to Know after Three Decades of Experience
Riccardo Lencioni, MD, PhD (Italy)
Y90 Radioembolization for Hepatocellular Carcinoma: Demonstrating Efficacy through Data
Riad Salem, MD (USA)
Advances in Transarterial Tumour Therapy: Does Novel Technology Mean Better Outcomes?
Thierry de Baere, MD (France)
Targeting Glucose Metabolism – A New Class of Agents for Transarterial Treatment of HCC?
Jean-François Geschwind, MD (USA)
18:30
19:30
Sirtex Symposium
07:30
08:30
Bristol-Myers Squibb Symposium
08:30
09:15
ILCA General Assembly
09:15
09:45
Coffee and Networking Break
09:45
10:45
State-of-the-Art Lecture 2: Fibrolamellar Carcinoma
Chair: Curtis C. Harris, MD (USA)
Speaker: Sanford M. Simon, PhD (USA)
10:45
12:15
General Session 5: From Drivers to Clinical Trials
Chairs: Sheng-Long Ye, MD, PhD (P. R. China) and Morris Sherman, MD, PhD (Canada)
12:15
12:30
Closing Ceremony